Extended dosing of monoclonal antibodies in multiple sclerosis

Zoé L. E. van Kempen*, Alyssa A. Toorop, Finn Sellebjerg, Gavin Giovannoni, Joep Killestein

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review


Over the past two decades, treatment options for patients with multiple sclerosis (MS) have increased exponentially. In the current therapeutic landscape, “no evidence of MS disease activity” is within reach in many of our patients. Minimizing risks of complications, improving treatment convenience, and decreasing health care costs are goals that are yet to be reached. One way to optimize MS therapy is to implement personalized or extended interval dosing. Monoclonal antibodies are suitable candidates for personalized dosing (by therapeutic drug monitoring) or extended interval dosing. An increasing number of studies are performed and underway reporting on altered dosing intervals of anti-α4β1-integrin treatment (natalizumab) and anti-CD20 treatment (ocrelizumab, rituximab, and ofatumumab) in MS. In this review, current available evidence regarding personalized and extended interval dosing of monoclonal antibodies in MS is discussed with recommendations for future research and clinical practice.
Original languageEnglish
JournalMultiple Sclerosis Journal
Early online date2021
Publication statusE-pub ahead of print - 2021

Cite this